- Home
- OCEAW vs VCYT Comparison
OCEAW vs VCYT Comparison
Compare OCEAW & VCYT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OCEAW
- VCYT
- Stock Information
- Founded
- OCEAW N/A
- VCYT 2006
- Country
- OCEAW United States
- VCYT United States
- Employees
- OCEAW 7
- VCYT N/A
- Industry
- OCEAW Biotechnology: Pharmaceutical Preparations
- VCYT Medical Specialities
- Sector
- OCEAW Health Care
- VCYT Health Care
- Exchange
- OCEAW Nasdaq
- VCYT Nasdaq
- Market Cap
- OCEAW N/A
- VCYT N/A
- IPO Year
- OCEAW 2021
- VCYT 2013
- Fundamental
- Price
- OCEAW $0.03
- VCYT $30.03
- Analyst Decision
- OCEAW
- VCYT Buy
- Analyst Count
- OCEAW 0
- VCYT 9
- Target Price
- OCEAW N/A
- VCYT $42.67
- AVG Volume (30 Days)
- OCEAW N/A
- VCYT 938.6K
- Earning Date
- OCEAW N/A
- VCYT 05-06-2025
- Dividend Yield
- OCEAW N/A
- VCYT N/A
- EPS Growth
- OCEAW N/A
- VCYT N/A
- EPS
- OCEAW N/A
- VCYT 0.31
- Revenue
- OCEAW N/A
- VCYT $445,764,000.00
- Revenue This Year
- OCEAW N/A
- VCYT $11.70
- Revenue Next Year
- OCEAW N/A
- VCYT $11.03
- P/E Ratio
- OCEAW N/A
- VCYT $97.16
- Revenue Growth
- OCEAW N/A
- VCYT 23.46
- 52 Week Low
- OCEAW N/A
- VCYT $18.61
- 52 Week High
- OCEAW N/A
- VCYT $47.32
- Technical
- Relative Strength Index (RSI)
- OCEAW N/A
- VCYT 34.55
- Support Level
- OCEAW N/A
- VCYT $30.99
- Resistance Level
- OCEAW N/A
- VCYT $34.19
- Average True Range (ATR)
- OCEAW 0.00
- VCYT 1.47
- MACD
- OCEAW 0.00
- VCYT 0.19
- Stochastic Oscillator
- OCEAW 0.00
- VCYT 23.81
About OCEAW Ocean Biomediacal Inc.
Ocean Biomedical Inc is a biopharmaceutical company that is focused on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases. The company is developing an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of Idiopathic Pulmonary Fibrosis and Hermansky-Pudlak Syndrome.